Shandong Sinder Technology Co., Ltd.
山东信得科技股份有限公司
Develops, produces and sells animal health products in the PRC, including veterinary vaccines, antibodies, Chinese veterinary medicines, drug formulations, and animal feed and additives for poultry, livestock, aquatic animals and pets. Ranked tenth in the PRC animal health market per CIC.
Filings
The documents are on HKEXnews; we link to the originals.
| 2026-10-14 | Re-filed AP | Application Proof (1st submission) | HKEXnews |
Key figures
Latest period: 5M2026 (to 2026-05-31). As printed in the filing; the full track record is in the company overview.
- Revenue
- RMB507.2 million
- Gross margin
- 49.7%
- Net profit (loss)
- RMB51.1 million
Matters the filing discloses
From the company’s latest filing; open a kind of matter to see how other companies disclosed it.
- One leased land not registered and filed
- Two leased properties without valid property ownership certificates
- Nine owned properties without real estate ownership certificates
- Insufficient payment of social insurance and housing provident fund
- Diagnostic test kits produced and used without registration
- Beijing Xinde involved in litigation over a guarantee dispute
- Customers settled payments through third-party payment arrangements
- Unauthorised external guarantees and guarantees for related parties
- Loans to third parties and related parties
- Revenue from five largest customers represented approximately 16% to 20% of revenue during the Track Record Period
- Purchases from the five largest raw material suppliers accounted for approximately 27.5% to 32.8%
- Customer Groups C and D are also the Company's suppliers
- Continuous decline in the number of distributors with the top ten distributors accounting for approximately 70% of distributor revenue
- Government procurement revenue obtained through tendering and subject to budget appropriation cycle
- Raw material costs accounted for approximately 65% to 68% of cost of sales, with sensitivity analysis conducted
- Change in the VAT calculation method for veterinary biological products from 2026
- Substantial growth in overseas revenue and operations through local partner model
- Sales subject to seasonal fluctuations, with higher sales from September to November
- High trade receivables, ageing over one year and increase in impairment provisions
- Inventories of approximately RMB160 million to RMB180 million with turnover days of 107 to 117 days
- Aggregate impairment of goodwill and fixed assets of RMB590 million recognised in respect of Shandong Haili in 2025
- Adjusted net profit excludes non-HKFRS items such as impairment of Shandong Haili
- Sharp decrease in government grants in 2025 leading to a 50.6% decrease in other income and gains
- Loans to connected persons and third parties fully impaired
- Procurement from Entity List suppliers and sales to sanctioned regions of concern such as Egypt
Other applicants in the same industry
All of them: Biotech & Pharma · Agriculture
- ACROBIOSYSTEMS CO., LTD北京百普赛斯生物科技股份有限公司
Develops, produces and sells biological reagents—recombinant proteins, antibodies and analytical assay kits—plus technical services supporting biopharmaceutical R&D in China and globally. Per Frost & Sullivan, ranked third globally in recombinant proteins with a 2.7% revenue share in 2025.
Develops and commercializes diagnostic and therapeutic radiopharmaceuticals, with a 13-asset pipeline including a registrational-stage lutetium-177 radioligand for neuroendocrine neoplasms and fluorine-18 PET diagnostic imaging agents, in China.
Produces and sells TCM decoction-ready products, traditional herbal preparations, wellness products and health management services to hospitals, medical trading companies, pharmacies, pharmaceutical companies and retail consumers across most Chinese provinces, Hong Kong, Taiwan and overseas markets. Ranked second in China with 0.4% market share in 2025.
Develops small-molecule drugs for autoimmune diseases and oncology, with one NMPA-approved drug (Mufemilast) and five clinical-stage candidates; markets drugs in China and holds patents in China, the US and other jurisdictions.
- Zhejiang Jingxin Pharmaceutical Co., Ltd.浙江京新药业股份有限公司
Pharmaceutical group in China developing and selling drugs focused on CNS disorders and cardiovascular/cerebrovascular diseases, including generics, the innovative drug Dimdazenil, TCM, biologics, APIs, and medical equipment. 2025 revenue was RMB4,069.4 million with net profit of RMB771.7 million.
- SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.深圳信立泰药业股份有限公司
Develops, produces, and sells pharmaceuticals and medical devices focused on cardiovascular-kidney-metabolic diseases in China, including innovative drugs, generics, and biosimilars. Ranked second in in-hospital sales of cardiovascular drugs in China in 2025 with an 11.3% market share, per Frost & Sullivan.
- ProteLight Pharmaceuticals (Jiangsu) Co., Ltd.普莱医药（江苏）股份有限公司
Develops antimicrobial peptide therapeutics focusing on anti-infectives and metabolic diseases. Core product PL-5 (Peceleganan) is a topical spray treating secondary infections of burn wounds and diabetic foot infections. Operates in China.
- Hangzhou Bangshun Pharmaceutical Co., Ltd.杭州邦顺制药股份有限公司
Develops and commercializes oral small-molecule drugs for oncology and autoimmune diseases, with a pipeline including NMPA-approved bezacitinib, a JAK inhibitor for myelofibrosis, and one registrational candidate, operating in China.